CS
INDP icon

Credit Suisse’s Indaptus Therapeutics INDP Stock Holding History

Credit Suisse’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-365
Closed -$179K – 4523
2021
Q1 		$179K Buy
+365
New +$191K ﹤0.01% 4144

Other funds holding INDP

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Credit Suisse's INDP Position: Q2 2021 in Review

Credit Suisse sold out of Indaptus Therapeutics (INDP) in Q2 2021, closing a stake of 365 shares — an estimated $179K sold.

Credit Suisse first reported a position in INDP in Q1 2021 and held it in 1 quarter. The position peaked at $179K in Q1 2021. 10 funds tracked by Wall St. Rank hold INDP as of Q2 2021.

  • Credit Suisse reported no remaining Indaptus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Credit Suisse sold 365 Indaptus Therapeutics shares in Q2 2021, an estimated $179K.
  • Credit Suisse first reported a position in Indaptus Therapeutics in Q1 2021 and held it in 1 quarter.
  • Credit Suisse's Indaptus Therapeutics position peaked at $179K in Q1 2021.
  • 10 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2021.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.